ReviewMedical oncology (Northwood, London, England)2017
Primary central nervous system lymphoma: essential points in diagnosis and management.
Review in Medical oncology (Northwood, London, England), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 28 citations in OpenAlex.
- Third ventricle non-Hodgkin lymphoma: An unusual presentation of primary central nervous system lymphoma.BMC neurology · 2026Article
- Article
- Longitudinally extensive transverse myelitis preceding primary central nervous system lymphoma: Spinal sentinel neuroinflammation.The journal of spinal cord medicine · 2023Article
- Treatment Options for Epstein-Barr Virus-Related Disorders of the Central Nervous System.Infection and drug resistance · 2023Review
- Bruton's tyrosine kinase inhibitors in the treatment of primary central nervous system lymphoma: A mini-review.Frontiers in oncology · 2022Review
- Primary Middle Cerebellar Peduncle Lymphoma with Primary Cervical Lymphoma: Repeated Misdiagnosis.The journal of international advanced otology · 2021Article
- Epigenetic Plasticity Enables CNS-Trafficking of EBV-infected B Lymphocytes.PLoS pathogens · 2021Article
- Review
- Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict chemotherapeutic responses and survival in primary central-nervous-system lymphoma.European radiology · 2021Article
- Cerebral MRI Mimicking Pachymeningeal Involvement Associated with Intrathecal TreatmentTurkish journal of haematology : official journal of Turkish Society of Haematology · 2020Article
- Histopathological variation in the demyelinating sentinel lesion of primary central nervous system lymphoma.Surgical neurology international · 2020Article
- Epstein-Barr Virus Infection in the Development of Neurological Disorders.Drug discovery today. Disease models · 2020Article
- Primary Central Nervous System Lymphoma: Molecular Pathogenesis and Advances in Treatment.Translational oncology · 2019Review
- Non-Hodgkin Lymphoma With Longitudinally Extensive Transverse Myelopathy as the Initial Symptom: A Case Report.Frontiers in oncology · 2019Article
- Primary CNS Lymphomas: Challenges in Diagnosis and Monitoring.BioMed research international · 2018Review
- The expression of PD-1 ligands and IDO1 by macrophage/microglia in primary central nervous system lymphoma.Journal of clinical and experimental hematopathology : JCEH · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary central nervous system lymphoma (PCNSL) is an extra-nodal non-Hodgkin lymphoma. PCNSL is defined as lymphoma involving the brain, leptomeninges, eyes, or spinal cord without evidence of lymphoma outside the CNS. Treatment includes induction with chemotherapy and consolidation with whole-brain radiotherapy or high-dose chemotherapy supported by autologous stem cell transplantation. High-dose methotrexate is the most important drug in cases with PCNSL, and this drug will be used in combination with small molecules, BTK inhibitors, new monoclonal antibodies, and checkpoint blockers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.